You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ridge Waveguide Structures in Magnesium-Doped Lithium Niobate

    SBC: ADVR, INC.            Topic: T401

    In this NASA Phase I STTR effort, the feasibility of fabricating isolated ridge waveguides in 5% magnesium-doped lithium niobate (5% MgO:LN) will be established. Ridge waveguides in MgO:LN will significantly improve the power handling and conversion efficiency, increase photonic component integration, and be well suited to space based applications. The key innovation in this effort is to combine ...

    STTR Phase I 2009 National Aeronautics and Space Administration
  2. Turbopump Design for Deep Throttling Capability

    SBC: Barber-Nichols, LLC            Topic: T802

    This project will demonstrate the benefits of a partial emission pump coupled with a zero net positive suction pressure inducer design to achieve robust, deep throttling capability. This pump application is well suited for 5k to 15k lbf thrust range rocket engines.

    STTR Phase II 2009 National Aeronautics and Space Administration
  3. Natural Mixtures from Expired Human Platelets for Periodontal Tissue Engineering

    SBC: SNOASIS MEDICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Some 1.8 million regenerative dental procedures were done in the U.S. in 2006. Of these, about 20% used a wound-healant product such as a recombinant growth factor (RGF) or concentrates of a patient's own platelets [requiring the use of a platelet concentrating system (PCS)]. Wound-healants are used as an attempt to accelerate healing and to improve patient ou ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Functional Tissue Engineering for Cartilage Repair

    SBC: Cytex Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Degenerative joint diseases such as osteoarthritis remain the source of significant pain and disability, affecting 20 million adults with an economic burden of over 40 billion per year to the United States. While joint replacement is a well-established procedure, its finite life span makes this treatment unacceptable for younger or more active individuals, of ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Heterogeneous Photocatalytic System for Water Remediation

    SBC: ELTRON RESEARCH & DEVELOPMENT, INCORPORATED            Topic: N/A

    DESCRIPTION (provided by applicant): We have defined a Phase I program for establishing a system that will destroy pharmaceuticals in drinking water by leveraging Eltron's PeroxEgen and proprietary photocatalysts which will be developed in Phase I research. PeroxEgen is an H2O2 and peracetic acid (PAA) generating device that is nearing commercial readiness. Wastewater, doped with PeroxEgen -gene ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Fast Spectral Imaging Device For Tumor Margin Mapping

    SBC: Zenalux Biomedical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The American Cancer Society estimates that a total of 240,430 new breast cancers were diagnosed in 2007 (178,400 new cases of invasive breast cancer, and 62,030 new cases of in situ breast cancer). Approximately 180,000 of these patients undergo breast conserving surgery (BCS), also called lumpectomy. Multiple recent studies show that a staggering 20-70% of the ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Development of ADAM10 Prodomain as a Therapeutic Agent

    SBC: BIOZYME, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent cancer therapies have focused on using biologics to target specific signal transduction pathways implicated in the tumor development or progression. For example, recombinant fusion proteins consisting of the extracellular domain of the immunoregluatory proteins and the constant (Fc) domain of immunoglobulin (IgG) represent a growing class of protein ther ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. The identification of novel negative allosteric modulators of the nicotinic recep

    SBC: Promiliad Biopharma Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner the drug discovery technology of the Promiliad Biopharma with the expertise of Professor Dennis McKay to identify novel and subtype selective negative allosteric modulators of the nicotinic acetylcholin ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Prevention Buffet: An Internet Prevention Resource for Middle Schools

    SBC: TANGLEWOOD RESEARCH INC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this STTR Phase I proposal is to develop a searchable Internet database of prevention lessons called Prevention Buffet. The database will allow middle school teachers to customize prevention efforts in their classrooms to the needs of their students, while providing them with guidance in selecting and implementing prevention lessons. Lessons will be ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. NF-kB Inhibition of Lung Ischemia Repurfusion Injury

    SBC: THERALOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) is a major problem in many clinical scenarios, including myocardial infarction and stroke. IRI is also a major problem in organ transplantation, because IRI is the major cause of primary graft failure and organ dysfunction after transplant. Increasingly, graft injury due to IRI at the time of implantation is recognized as a maj ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government